Limited Submission Opportunity: 2023 V Foundation Adult Translational Cancer Research Awards (Therapeutic Resistance)

Applications due March 1

This is a joint competition for VU and VUMC investigators. All investigators should follow these instructions.

Vanderbilt (VU and VUMC, collaboratively) may choose one nominee for the V Foundation 2023 Adult Translational Cancer Research (Therapeutic Resistance) Grants Program. The grant provides $800,000 in four annual installments of $200,000. Indirect costs up to a maximum of 10 percent within the total award are permitted.

The V Foundation invites applications for adult cancer research that moves a novel strategy from the laboratory into a human clinical trial or uses specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than three years from the end of the grant. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.

This RFA is specifically for adult cancer research that falls into preclinical/translational research as described above. This year, the foundation has special interest and funding for therapeutic resistance and welcomes research projects in this area. Please note that research areas not included in this scope are epidemiology, behavioral science and health services research.

Applicant eligibility

By March 15, 2023, applicants must meet the following criteria:

  • Hold a tenure-track or tenured faculty position at their cancer research institution. Non-promotable adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for principal investigator nomination.

Internal selection process

Anyone interested in being considered as Vanderbilt’s nominee for this opportunity must submit the following (in PDF format) to  by 11:59 p.m. on March 1, 2023. Late applications will not be considered.

  1. Brief (2-page maximum) research plan including summary budget;
  2. Statement of support from department chair/center director;
  3. NIH Biosketch or 5-page CV.

Submissions should reference “2023 V Translational Research Award–Adult Cancer Research” in the subject line of the email.

A short nomination form for Vanderbilt’s selected candidate will be submitted to the V Foundation by March 15, 2023. The candidate will then receive an invitation to submit a full application to the sponsor by April 24, 2023.

Email with any questions about the program, foundation or internal review process.